Dr Reddy’s Laboratories has secured European Commission approval for AVT03, its biosimilar of Prolia and Xgeva used in treating osteoporosis and bone-related conditions. Developed by Alvotech, the product will be commercialised by Dr Reddy’s across the US, Europe, and other market
Hyderabad: The Indian pharma industry has generated remarkable growth in the past decades fueled by increasing burden of diseases and aspirations to be the key generics, biosimilar and vaccine manufacturer for the world markets. Informa Pharma Intelligence’s ‘Indian Biosimilars Report’ shows that India leads the way with 127 products, which is the highest number of […]
